Despite inconsistent findings [23,35], HBVr has been observed in RA patients with concomitant CHB after receiving b/tsDMARDs, such as anti-TNF-α therapy [11], abatacept [22], tocilizumab [21,36], and tofacitinib [24]. The gene discussed is TNF; the disease is rheumatoid arthritis.